The Food and Drug Administration (FDA) announced a new date for the previously canceled public meeting on "Patient-Focused Drug Development for Vitiligo," now scheduled for March 8, 2021, in a virtual format. This meeting aims to gather patient input on how vitiligo affects their daily lives, their views on current treatment options, and how they decide on treatments. Participants can submit comments electronically or by mail until May 10, 2021, using the docket number FDA-2020-N-0255. The FDA seeks to understand patient perspectives to improve understanding and treatment approaches for vitiligo.
Simple Explanation
The FDA wants to hear from people with a skin condition called vitiligo to learn how it affects their lives and what they think about treatments, and they’ve set up an online meeting on March 8, 2021, where people can share their thoughts.